siRNA therapy for cancer and non-lethal diseases such as arthritis and osteoporosis

Bibliography

• Senolt L, Vencovsky J, Pavelka K, Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009;9:102-7
   PubMed Web of Science ®Google Scholar
• Evans CH. Gene therapy for bone healing. Expert Rev Mol Med 2010;12:e18
   Google Scholar
• Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000;404:293-6
   PubMed Web of Science ®Google Scholar
• Chen M, Granger AJ, Vanbrocklin MW, Inhibition of avian leukosis virus replication by vector-based RNA interference. Virology 2007;365:464-72
   PubMed Web of Science ®Google Scholar
• Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007;121:64-73
   PubMed Web of Science ®Google Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457:426-33
   PubMed Web of Science ®Google Scholar
• Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J Control Release 2009;134:158-68
   PubMed Web of Science ®Google Scholar
• Beyerle A, Irmler M, Beckers J, Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol Pharm 2010;7:727-37
   PubMed Web of Science ®Google Scholar
• Evans C. Arthritis gene therapy trials reach phase II. J Rheumatol 2010;37:683-5
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, Gollob J, Gamba-Vitalo C, A status report on RNAi therapeutics. Silence 2010;1:14
   PubMedGoogle Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9:57-67
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 2010;123:1183-9
   PubMed Web of Science ®Google Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJ, The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009;17:1225-33
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005;19:311-30
   PubMed Web of Science ®Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009;66:2873-96
   PubMed Web of Science ®Google Scholar
• Baker M. RNA interference: homing in on delivery. Nature 2010;464:1225-8
   Web of Science ®Google Scholar
• Baker M. RNA interference: from tools to therapies. Nature 2010;464:1225
   Web of Science ®Google Scholar
• Seiler MP, Cerullo V, Lee B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr Gene Ther 2007;7:297-305
   PubMed Web of Science ®Google Scholar
• Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007;7:325-33
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007;7:316-24
   PubMed Web of Science ®Google Scholar
• Romano G. Current development of nonviral-mediated gene transfer. Drug News Perspect 2007;20:227-31
   PubMed Web of Science ®Google Scholar
• Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J 2007;9:E92-104
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 2009;26:657-66
   PubMed Web of Science ®Google Scholar
• de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008;19:125-32
   PubMed Web of Science ®Google Scholar
• Andersen MO, Howard KA, Kjems J. RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications. Methods Mol Biol 2009;555:77-86
   PubMedGoogle Scholar
• Howard KA, Paludan SR, Behlke MA, Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17:162-8
   PubMed Web of Science ®Google Scholar
• Lavertu M, Methot S, Tran-Khanh N, Buschmann MD. High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 2006;27:4815-24
   PubMed Web of Science ®Google Scholar
• Jere D, Jiang HL, Arote R, Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin Drug Deliv 2009;6:827-34
   PubMed Web of Science ®Google Scholar
• Nguyen J, Xie X, Neu M, Effects of cell-penetrating peptides and pegylation on transfection efficiency of polyethylenimine in mouse lungs. J Gene Med 2008;10:1236-46
   PubMed Web of Science ®Google Scholar
• Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J 2009;11:195-203
   PubMed Web of Science ®Google Scholar
• Beyerle A, Hobel S, Czubayko F, In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro 2009;23:500-8
   PubMed Web of Science ®Google Scholar
• Moschos SA, Jones SW, Perry MM, Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007;18:1450-9
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther 2006;13:1313-19
   PubMed Web of Science ®Google Scholar
• Lewis DL, Wolff JA. Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 2007;59:115-23
   PubMed Web of Science ®Google Scholar
• Romero NB, Braun S, Benveniste O, Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 2004;15:1065-76
   PubMed Web of Science ®Google Scholar
• Kuhn R, Streif S, Wurst W. RNA interference in mice. Handb Exp Pharmacol 2007;(178):149-76
   PubMedGoogle Scholar
• Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol 2006;4:1-15
   Google Scholar
• Inoue A, Takahashi KA, Mazda O, Electro-transfer of small interfering RNA ameliorated arthritis in rats. Biochem Biophys Res Commun 2005;336:903-8
   PubMed Web of Science ®Google Scholar
• Nakajima A. Application of cellular gene therapy for rheumatoid arthritis. Mod Rheumatol 2006;16:269-75
   PubMedGoogle Scholar
• Akita H, Kogure K, Moriguchi R, Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 2010;143:311-17
   PubMed Web of Science ®Google Scholar
• Evans CH, Ghivizzani SC, Robbins PD. Orthopedic gene therapy in 2008. Mol Ther 2009;17:231-44
   PubMed Web of Science ®Google Scholar
• Woods JM, Katschke KJ, Volin MV, IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol 2001;166:1214-22
   PubMed Web of Science ®Google Scholar
• Woods JM, Amin MA, Katschke KJ Jr, Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther 2002;13:381-93
   PubMed Web of Science ®Google Scholar
• Khoury M, Courties G, Fabre S, Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum 2010;62:765-70
   PubMed Web of Science ®Google Scholar
• Lai Kwan LQ, King Hung KO, Zheng BJ, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008;105:14993-8
   PubMed Web of Science ®Google Scholar
• Kramer PR, Puri J, Bellinger LL. Knockdown of FcgammaRIII in an arthritic temporomandibular joint reduced the nociceptive response. Arthritis Rheum 2010. [Epub ahead of print ]
   Google Scholar
• Khoury M, Louis-Plence P, Escriou V, Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 2006;54:1867-77
   PubMed Web of Science ®Google Scholar
• Nakashima-Matsushita N, Homma T, Yu S, Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1609-16
   PubMed Web of Science ®Google Scholar
• Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-62
   PubMed Web of Science ®Google Scholar
• Cheng H, Zhu JL, Zeng X, Targeted gene delivery mediated by folate-polyethylenimine-block-poly(ethylene glycol) with receptor selectivity. Bioconjug Chem 2009;20:481-7
   PubMed Web of Science ®Google Scholar
• Zheng X, Suzuki M, Ichim TE, Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010;184:6457-64
   PubMed Web of Science ®Google Scholar
• Aouadi M, Tesz GJ, Nicoloro SM, Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458:1180-4
   PubMed Web of Science ®Google Scholar
• Inoue A, Takahashi KA, Mazda O, Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets. Mod Rheumatol 2009;19:125-33
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50
   PubMed Web of Science ®Google Scholar
• Schett G, Middleton S, Bolon B, Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005;52:1604-11
   PubMed Web of Science ®Google Scholar
• Zwerina J, Hayer S, Tohidast-Akrad M, Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90
   PubMed Web of Science ®Google Scholar
• Fernandes J, Tardif G, Martel-Pelletier J, In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154:1159-69
   PubMed Web of Science ®Google Scholar
• Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther 2009;16:944-52
   PubMed Web of Science ®Google Scholar
• Chen LX, Lin L, Wang HJ, Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008;16:174-84
   PubMed Web of Science ®Google Scholar
• Takahashi D, Iwasaki N, Kon S, Down-regulation of cathepsin K in synovium leads to progression of osteoarthritis in rabbits. Arthritis Rheum 2009;60:2372-80
   PubMed Web of Science ®Google Scholar
• Seong JM, Kim BC, Park JH, Stem cells in bone tissue engineering. Biomater Mater 2010;5(6):062001
   Google Scholar
• Wan DC, Pomerantz JH, Brunet LJ, Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 2007;282:26450-9
   PubMed Web of Science ®Google Scholar
• Kwong FN, Richardson SM, Evans CH. Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells. Arthritis Res Ther 2008;10:R65
   PubMedGoogle Scholar
• Wang Y, Grainger DW. siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharm Res 2010;27:1273-84
   PubMed Web of Science ®Google Scholar
• Fahid FS, Jiang J, Zhu Q, Application of small interfering RNA for inhibition of lipopolysaccharide-induced osteoclast formation and cytokine stimulation. J Endod 2008;34:563-9
   PubMed Web of Science ®Google Scholar
• Lu M, Rabie AB. Matrix metalloproteinase-9 regulates graft bone resorption. Angle Orthod 2006;76:598-604
   PubMed Web of Science ®Google Scholar
• Sundaram K, Nishimura R, Senn J, RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-78
   PubMed Web of Science ®Google Scholar
• Selinger CI, Day CJ, Morrison NA. Optimized transfection of diced siRNA into mature primary human osteoclasts: inhibition of cathepsin K mediated bone resorption by siRNA. J Cell Biochem 2005;96:996-1002
   PubMed Web of Science ®Google Scholar
• Pang M, Martinez AF, Fernandez I, AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene 2007;403:151-8
   PubMed Web of Science ®Google Scholar
• Yudoh K, Matsuno H, Osada R, Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum 2000;43:2178-88
   PubMed Web of Science ®Google Scholar
• Okada Y, Tanaka Y. Immune signals in the context of secondary osteoporosis. Histol Histopathol 2004;19:863-6
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005;4:325-8
   PubMedGoogle Scholar
• Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Rheumatol Rep 2006;8:63-9
   PubMedGoogle Scholar
• Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14
   PubMed Web of Science ®Google Scholar
• Zhang H, Cheng JQ, Huang Q, Increasing alcohol-induced osteogenesis of human bone marrow-derived mesenchymal cells using siRNA transient suppression of peroxisome proliferator activated receptor gamma: an in vitro experiment study. Zhonghua Yi Xue Za Zhi 2008;88:2603-8
   PubMedGoogle Scholar
• Liu LF, Shen WJ, Zhang ZH, Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARgamma and adiponectin J Cell Physiol 2010. [Epub ahead of print]
   Google Scholar
• Hayami T, Kapila YL, Kapila S. MMP-1 (collagenase-1) and MMP-13 (collagenase-3) differentially regulate markers of osteoblastic differentiation in osteogenic cells. Matrix Biol 2008;27:682-92
   PubMed Web of Science ®Google Scholar
• Holt G, Murnaghan C, Reilly J, Meek RM. The biology of aseptic osteolysis. Clin Orthop Relat Res 2007;460:240-52
   PubMed Web of Science ®Google Scholar
• Peng X, Tao K, Cheng T, Efficient Inhibition of wear debris-induced inflammation by locally delivered siRNA. Biochem Biophys Res Commun 2008;377:532-7
   PubMed Web of Science ®Google Scholar
• Cheng T, Zhang X. NFkappaB gene silencing inhibits wear particles-induced inflammatory osteolysis. Med Hypotheses 2008;71:727-9
   PubMed Web of Science ®Google Scholar
• Xu J, Wu HF, Ang ES, NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009;20:7-17
   PubMed Web of Science ®Google Scholar
• Darwech I, Otero J, Alhawagri M, Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis. J Cell Biochem 2009;108:1337-45
   PubMed Web of Science ®Google Scholar
• Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11:184-92
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Heidel JD, Bartlett DW, Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005;65:8984-92
   PubMed Web of Science ®Google Scholar
• Guan H, Zhou Z, Wang H, A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11:2662-9
   PubMed Web of Science ®Google Scholar
• Beauchamp E, Bulut G, Abaan O, GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J Biol Chem 2009;284:9074-82
   PubMed Web of Science ®Google Scholar
• Smith R, Owen LA, Trem DJ, Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405-16
   PubMed Web of Science ®Google Scholar
• Luo X, Chen J, Song WX, Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008;88:1264-77
   PubMed Web of Science ®Google Scholar
• Kim DW, Seo SW, Cho SK, Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res 2007;25:820-8
   PubMed Web of Science ®Google Scholar
• Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95
   PubMed Web of Science ®Google Scholar
• Guise TA, O'Keefe R, Randall RL, Terek RM. Molecular biology and therapeutics in musculoskeletal oncology. J Bone Joint Surg Am 2009;91:724-32
   PubMed Web of Science ®Google Scholar
• Cheema SK, Chen E, Shea LD, Mathur AB. Regulation and guidance of cell behavior for tissue regeneration via the siRNA mechanism. Wound Repair Regen 2007;15:286-95
   PubMed Web of Science ®Google Scholar
• Evans CH, Ghivizzani SC, Smith P, Using gene therapy to protect and restore cartilage. Clin Orthop Relat Res 2000;(379 Suppl):S214-19
   Google Scholar
• Evans CH, Robbins PD. Genetically augmented tissue engineering of the musculoskeletal system. Clin Orthop Relat Res 1999;(367 Suppl):S410-18
   Google Scholar
• Wang ZH, Yang ZQ, He XJ, Lentivirus-mediated knockdown of aggrecanase-1 and -2 promotes chondrocyte-engineered cartilage formation in vitro. Biotechnol Bioeng 2010. [Epub ahead of print]
   Google Scholar
• Seki S, Asanuma-Abe Y, Masuda K, Effect of small interference RNA (siRNA) for ADAMTS5 on intervertebral disc degeneration in the rabbit anular needle-puncture model. Arthritis Res Ther 2009;11:R166
   PubMedGoogle Scholar
• Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 2007;317:580
   PubMed Web of Science ®Google Scholar